These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 27334353)

  • 1. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
    Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
    Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of vascular calcification and mortality in patients with ESRD.
    Scialla JJ; Kao WH; Crainiceanu C; Sozio SM; Oberai PC; Shafi T; Coresh J; Powe NR; Plantinga LC; Jaar BG; Parekh RS
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):745-55. PubMed ID: 24458076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.
    Edmonston D; Wojdyla D; Mehta R; Cai X; Lora C; Cohen D; Townsend RR; He J; Go AS; Kusek J; Weir MR; Isakova T; Pencina M; Wolf M;
    Am J Kidney Dis; 2019 Dec; 74(6):771-781. PubMed ID: 31445926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
    Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
    Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.
    Lee JE; Kim HJ; Moon SJ; Nam JS; Kim JK; Kim SK; Yun GY; Ha SK; Park HC
    Korean J Intern Med; 2013 Nov; 28(6):668-77. PubMed ID: 24307842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Associations of Blood Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin with Progression from CKD to ESRD.
    Alderson HV; Ritchie JP; Pagano S; Middleton RJ; Pruijm M; Vuilleumier N; Kalra PA
    Clin J Am Soc Nephrol; 2016 Dec; 11(12):2141-2149. PubMed ID: 27852662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac troponin T elevation at dialysis initiation is associated with all-cause and cardiovascular mortality on dialysis in patients without diabetic nephropathy.
    Hayashi T; Kimura T; Yasuda K; Sasaki K; Obi Y; Rakugi H; Isaka Y
    Clin Exp Nephrol; 2017 Apr; 21(2):333-341. PubMed ID: 27178276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
    Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum sodium levels with all-cause and cardiovascular mortality in chronic kidney disease: Results from a prospective observational study.
    Chiu DY; Kalra PA; Sinha S; Green D
    Nephrology (Carlton); 2016 Jun; 21(6):476-82. PubMed ID: 26426983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.
    Ford ML; Smith ER; Tomlinson LA; Chatterjee PK; Rajkumar C; Holt SG
    Nephrol Dial Transplant; 2012 Feb; 27(2):727-33. PubMed ID: 21750158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular calcification in patients with nondialysis CKD over 3 years.
    Górriz JL; Molina P; Cerverón MJ; Vila R; Bover J; Nieto J; Barril G; Martínez-Castelao A; Fernández E; Escudero V; Piñera C; Adragao T; Navarro-Gonzalez JF; Molinero LM; Castro-Alonso C; Pallardó LM; Jamal SA
    Clin J Am Soc Nephrol; 2015 Apr; 10(4):654-66. PubMed ID: 25770175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
    Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
    Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.
    Wohlfahrt P; Melenovsky V; Kotrc M; Benes J; Jabor A; Franekova J; Lemaire S; Kautzner J; Jarolim P
    JACC Heart Fail; 2015 Oct; 3(10):829-39. PubMed ID: 26450001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of serum chloride level with mortality and cardiovascular events in chronic kidney disease: the CKD-ROUTE study.
    Mandai S; Kanda E; Iimori S; Naito S; Noda Y; Kikuchi H; Akazawa M; Oi K; Toda T; Sohara E; Okado T; Sasaki S; Rai T; Uchida S
    Clin Exp Nephrol; 2017 Feb; 21(1):104-111. PubMed ID: 27039905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of BP with Death, Cardiovascular Events, and Progression to Chronic Dialysis in Patients with Advanced Kidney Disease.
    Palit S; Chonchol M; Cheung AK; Kaufman J; Smits G; Kendrick J
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):934-40. PubMed ID: 25979975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study.
    Hasegawa T; Sakamaki K; Koiwa F; Akizawa T; Hishida A;
    Clin Exp Nephrol; 2019 Feb; 23(2):189-198. PubMed ID: 30069609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Serum Ig Free Light Chains with Mortality and ESRD among Patients with Nondialysis-Dependent CKD.
    Ritchie J; Assi LK; Burmeister A; Hoefield R; Cockwell P; Kalra PA
    Clin J Am Soc Nephrol; 2015 May; 10(5):740-9. PubMed ID: 25825483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.